药品注册申请号:020636
申请类型:NDA (新药申请)
申请人:BOEHRINGER INGELHEIM
申请人全名:BOEHRINGER INGELHEIM PHARMACEUTICALS INC
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 VIRAMUNE NEVIRAPINE TABLET;ORAL 200MG Yes No AB 1996/06/21 1996/06/21 Discontinued
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2022/06/10 SUPPL-52(补充) Approval Labeling STANDARD
2018/09/24 SUPPL-50(补充) Approval Labeling STANDARD
2017/03/27 SUPPL-48(补充) Approval Labeling STANDARD
2016/04/14 SUPPL-47(补充) Approval Manufacturing (CMC) PRIORITY
2014/01/27 SUPPL-44(补充) Approval Labeling STANDARD
2012/11/09 SUPPL-42(补充) Approval Labeling STANDARD
2011/11/09 SUPPL-39(补充) Approval Labeling STANDARD
2011/05/06 SUPPL-38(补充) Approval REMS N/A
2011/03/25 SUPPL-37(补充) Approval Labeling STANDARD
2011/01/07 SUPPL-36(补充) Approval REMS N/A
2010/07/20 SUPPL-35(补充) Approval Labeling STANDARD
2010/01/13 SUPPL-32(补充) Approval Labeling STANDARD
2008/06/24 SUPPL-27(补充) Approval Efficacy PRIORITY
2007/08/16 SUPPL-29(补充) Approval Labeling STANDARD
2007/04/13 SUPPL-26(补充) Approval Labeling STANDARD
2005/02/24 SUPPL-25(补充) Approval Labeling STANDARD
2004/05/24 SUPPL-22(补充) Approval Labeling STANDARD
2003/12/22 SUPPL-21(补充) Approval Labeling STANDARD
2003/07/29 SUPPL-20(补充) Approval Labeling STANDARD
2002/12/31 SUPPL-16(补充) Approval Labeling STANDARD
2002/12/18 SUPPL-19(补充) Approval Manufacturing (CMC) PRIORITY
2002/03/27 SUPPL-17(补充) Approval Efficacy UNKNOWN
2001/02/23 SUPPL-15(补充) Approval Manufacturing (CMC) PRIORITY
2000/11/06 SUPPL-14(补充) Approval Labeling STANDARD
2000/08/10 SUPPL-13(补充) Approval Labeling STANDARD
1999/10/25 SUPPL-11(补充) Approval Labeling STANDARD
1999/08/05 SUPPL-12(补充) Approval Manufacturing (CMC) PRIORITY
1999/06/01 SUPPL-10(补充) Approval Manufacturing (CMC) PRIORITY
1998/09/11 SUPPL-9(补充) Approval Efficacy STANDARD
1998/05/20 SUPPL-7(补充) Approval Labeling STANDARD
1998/05/20 SUPPL-2(补充) Approval Efficacy STANDARD
1998/01/16 SUPPL-3(补充) Approval Manufacturing (CMC) PRIORITY
1997/11/21 SUPPL-1(补充) Approval Manufacturing (CMC) PRIORITY
1997/09/24 SUPPL-4(补充) Approval Manufacturing (CMC) PRIORITY
1997/09/19 SUPPL-5(补充) Approval Manufacturing (CMC) PRIORITY
1996/06/21 ORIG-1(原始申请) Approval Type 1 - New Molecular Entity PRIORITY
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
001 5366972 2011/11/22 U-167 PDF格式**本条是由Drugfuture回溯的历史信息**
5366972*PED 2012/05/22 PDF格式**本条是由Drugfuture回溯的历史信息**
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
与本品治疗等效的药品
活性成分:NEVIRAPINE 剂型/给药途径:TABLET;ORAL 规格:200MG 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
020636 001 NDA VIRAMUNE NEVIRAPINE TABLET;ORAL 200MG Discontinued Yes No AB 1996/06/21 BOEHRINGER INGELHEIM
077521 001 ANDA NEVIRAPINE NEVIRAPINE TABLET;ORAL 200MG Prescription No No AB 2012/05/22 AUROBINDO
077956 001 ANDA NEVIRAPINE NEVIRAPINE TABLET;ORAL 200MG Prescription No No AB 2012/05/22 CIPLA
078195 001 ANDA NEVIRAPINE NEVIRAPINE TABLET;ORAL 200MG Prescription No No AB 2012/05/22 STRIDES PHARMA
078584 001 ANDA NEVIRAPINE NEVIRAPINE TABLET;ORAL 200MG Prescription No No AB 2012/05/22 HETERO LABS LTD III
078644 001 ANDA NEVIRAPINE NEVIRAPINE TABLET;ORAL 200MG Discontinued No No AB 2012/05/22 PRINSTON INC
202523 001 ANDA NEVIRAPINE NEVIRAPINE TABLET;ORAL 200MG Prescription No No AB 2012/05/22 MYLAN PHARMS INC
203080 001 ANDA NEVIRAPINE NEVIRAPINE TABLET;ORAL 200MG Prescription No No AB 2012/05/22 MICRO LABS LTD
090688 001 ANDA NEVIRAPINE NEVIRAPINE TABLET;ORAL 200MG Prescription No Yes AB 2019/01/14 MACLEODS PHARMS LTD
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database